Chemotherapy Doctors Abroad — Page 5

Forbes named Dr. Tabernero one of Spain's 5 most influential cancer leaders. Former President of the European Society for Medical Oncology.

• Director of the Vall d’Hebrón Institute of Oncology
• Specializes in molecular targeted therapies and personalized cancer treatments
• Author of over 70 papers on innovative cancer treatments
• Conducts clinical trials for new colon cancer therapies

Professor Cicin brings 29 years of experience of oncology expertise, specializing in chemotherapy at İstinye University Liv Hospital Topkapı.

• Board-certified in medical oncology since 2004
• Fellowship-trained at Trakya University Faculty of Medicine
• Professor of Medical Oncology at Trakya University
• Published researcher in oncology treatments

Assoc. Prof. Atakan Topcu specializes in solid tumors and cancer-related conditions, bringing extensive expertise in targeted therapies and immunotherapy.

• Published over 50 scientific articles in oncology
• Member of ESMO and Turkish Society of Medical Oncology
• Focuses on geriatric oncology and cancer-related malnutrition
• Fellowship-trained in Medical Oncology at Bezmialem Vakıf University

Dr. Ercan Ozden specializes in chemotherapy, combining years of internal medicine expertise with focused medical oncology training at Kocaeli University.

• Board-certified in internal medicine with over 27 years of experience of clinical experience
• Trained at Istanbul University's prestigious Cerrahpaşa Faculty of Medicine
• Completed medical oncology subspecialty at Kocaeli University
• Has worked across diverse hospital settings, from state to university hospitals

Dr. Alemdar specializes in medical oncology with extensive training at Akdeniz University – a leading institution in Turkey.

• Board-certified in medical oncology since 2018
• Over 20 years of experience of experience in internal medicine and oncology
• Works at Medical Park Antalya Hospital Complex
• Member of the Turkish Medical Association

Prof. Ben Boursi leads research on microbiome prognostic factors in cancer therapies – merging cutting-edge science with clinical oncology at Sheba Medical Center.

• Specializes in gastrointestinal cancers with focused training at University of Pennsylvania and MD Anderson
• Founder of ECOG-ACRIN Microbiome Working Group – pioneering microbial modulation treatments
• Develops predictive models for colorectal and pancreatic cancers undergoing clinical trials
• Board-certified in both Internal Medicine and Medical Oncology by Israeli medical boards
• Teaches host-microbiome interactions at Tel Aviv University's medical school

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Assoc. Prof. Dr. Iyikesici specializes in metabolically supported chemotherapy – a tailored approach combining traditional methods with metabolic therapies at Central Hospital.

• Focuses on breast, lung, and gastrointestinal cancers
• Pioneers metabolic therapies like ketogenic diet in treatment plans
• Published peer-reviewed research on cancer treatment outcomes
• Offers hyperthermia and hyperbaric oxygen as complementary therapies

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

With over 20 years of oncology expertise, Dr. Lucía González Cortijo leads Quironsalud Madrid's oncology department and specializes in breast and gynecologic cancers.

• Focuses on personalized treatments, including immunotherapy and targeted therapies
• Principal investigator in 20+ clinical trials for breast cancer
• Member of ESMO, ASCO, and GEICAM research groups
• Founder of 'Corre en Rosa' to support cancer patients through physical activity
• Trained at MD Anderson Cancer Center Madrid

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Ivetta Danylesko specializes in chemotherapy at Sheba Medical Center, bringing expert care tailored to individual patient needs.

• Specializes in chemotherapy protocols
• Practices at Sheba Medical Center, a top-tier facility
• Focuses on personalized treatment approaches

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Uzm. Dr. Erkan Göcen is a Radiation Oncology Specialist at Çerkezköy Private Optimed Hospital (Optimed Health Group). He graduated from İstanbul University, İstanbul Faculty of Medicine (Çapa) in 2003.

Career: He trained and practiced in Radiation Oncology from 2010 to 2012. He worked in public and private health institutions from 2012 to 2016. He served in the private medical sector as a Radiation Oncology Specialist from 2016 to 2023. He has been at Optimed Hospital since 2024.

Clinical interests: cancers of the brain, head and neck, esophagus, stomach, colorectal, pancreas, prostate, bladder, lung, soft tissues (sarcomas), skin, uterus and cervix, and breast. Affiliations: Turkish Society for Radiation Oncology (TROD) and Tekirdağ Medical Chamber. Languages: English and Turkish.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Clinical Director of a Multidisciplinary Breast Unit with 322 peer-reviewed publications – Dr. Kuemmel leads breast cancer research at Kliniken Essen-Mitte.

• Executive Board Member of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie)
• ESMO Faculty member for Breast Cancer
• Global PI and head of 27 clinical investigations and trials
• Member of multiple prestigious oncology societies including ESMO and ASCO